The Team

David M Parry - Chief Operating Officer

Dave has over 17 years experience in pharmaceutical discovery gained within the biotech and biopharmaceutical industry.  Following a BSc in chemistry from University of Durham and a PhD in organic synthesis from Exeter, Dave spent two years in the USA working in the labs of Prof Philip D Magnus FRS.  Starting his career as a medicinal chemist with Celltech Dave rapidly developed an interest in drug discovery technologies and made the move to Chiroscience in Cambridge to head up their combinatorial chemistry effort.  After the acquisition of Chiroscience by Celltech he continued to strengthen both his scientific and management skills leading the Exploratory Chemistry section at the Cambridge site, responsibilities including high throughput chemistry, analytical chemistry and the computational chemistry group.  When UCB acquired Celltech in 2004 Dave had the opportunity to play a key role in small molecule discovery technologies and joined Cyclofluidic from UCB where he was most recently Director, Technology within Research.

Chris Selway - Chief Technology Officer

Prior to joining Cyclofluidic, Chris was employed at Pfizer Global R & D in Sandwich, UK as a Senior Principal Scientist.  He brings considerable experience in pharmaceutical discovery technologies development and had been leading the development of a microfluidic synthesis-assay platform for hit to lead discovery within Pfizer. Following graduation with a BSc in Chemistry from Loughborough University Chris has accumulated 26 years experience in pharmaceutical research at Pfizer, and has broad knowledge and expertise in chemical technology development and modern organic synthesis techniques. He was a founder member of the Pfizer Library Design and Production group with responsibility for development and implementation of automated systems for synthesis, analysis and purification of compound libraries. In 1997 Chris was awarded a Pfizer Individual Achievement Award for outstanding contribution to parallel synthesis and chemistry automation and in 2000 was awarded a Pfizer Team Achievement Award as member of the Autopurification Team for innovative design and delivery of a world leading system for the efficient purification of library compounds. More recently Chris has focused on applying flow chemistry and microfluidic technologies to enhance the drug discovery process. Externally, Chris is currently collaborating with Professor Steve Ley at Cambridge University, with a focus on flow chemistry; and is a member of the organising committee of the United Kingdom Automated Synthesis Forum (UKASF).

Elizabeth Farrant - Chief Business Officer

Elizabeth started her career in pharmaceutical research at SmithKline Beecham, initially as part of the highly innovative combinatorial chemistry and chemical technology department and then later in the medicinal chemistry department where she worked on protease inhibitor projects. In 2001 she moved to the newly created technology development department of the merged GSK where she led a team working in chemistry and cell biology with particular focus on the ground breaking areas of flow chemistry and microfluidic cell biology. In 2007 she moved to Pfizer Sandwich to lead new initiatives in flow synthesis and “flow discovery” which in 2009 was spun out in collaboration with UCB, as Cyclofluidic Ltd. Elizabeth assumed responsibility for other chemical technologies functions including high throughput reaction optimisation, bulk synthesis, labelled compound synthesis and hydrogenation and then in 2008 took on additional responsibility for analytical sciences. Since the creation of Cyclofluidic she has been closely involved as the Pfizer scientific lead, member of the SAB and observer on the board, finally joining Cyclofluidic as Chief Business Officer in 2011